Dr. Arezu Jahani-Asl at the University of Ottawa has identified a hidden molecular partnership that explains why glioblastoma, the most malignant and treatment-resistant brain cancer in adults, consistently defeats our best therapeutic efforts. The discovery centers on two proteins—OSMR and CLIC1—that work together as a coordinated signaling axis, a finding that could reshape how researchers design next-generation treatments for this devastating disease.
Glioblastoma has long mystified oncologists because tumors seem to possess an almost uncanny ability to adapt, recruit surrounding cells, and switch survival pathways faster than therapy can stop them. The conventional approach has been to target single downstream effects, picking off one survival mechanism at a time. But Jahani-Asl's research, published in Signal Transduction and Targeted Therapy and conducted in collaboration with scientists across Canada, Italy, and the United States, reveals something more fundamental: a central control node that orchestrates multiple tumor-promoting processes simultaneously.
At the heart of this system sits the Oncostatin M receptor, or OSMR. Rather than functioning as a simple on-off switch, OSMR behaves like an orchestrator of tumor progression, integrating signals from the tumor microenvironment to drive aggressive tumor cell states linked to treatment resistance. The protein plays a critical role in supporting brain tumor stem cells—the particularly dangerous population of cells responsible for tumor recurrence and relapse. OSMR does this partly by boosting the energy production systems cancer cells depend on to survive stress.
The study's most significant discovery emerged when Jahani-Asl's team mapped the full network of proteins interacting with OSMR. They identified chloride intracellular channel 1, known as CLIC1, as a crucial regulator within this system. CLIC1 has long been something of a hidden player in cancer biology, but this research illuminates its role as a molecular switchboard helping tumor cells manage stress, movement, and survival.
What makes the OSMR-CLIC1 relationship particularly important is that it functions as a self-reinforcing loop. OSMR regulates CLIC1 function, while CLIC1, in turn, supports OSMR-driven signaling. This crosstalk creates a tightly coordinated system that fuels glioblastoma's aggressive behavior. Using advanced electrophysiological techniques, the research team revealed this previously unknown bidirectional relationship for the first time, uncovering the biophysical properties of this mysterious channel.
The functional significance is clear: when CLIC1 is genetically deleted, the entire signaling system begins to collapse, resulting in measurable slowdown in glioblastoma progression. This underscores how vital this protein partnership is to sustaining the disease's key pathways.
Perhaps most promising for future treatment, Jahani-Asl's team has already mapped the interaction domain between OSMR and CLIC1, positioning researchers to design small peptides capable of halting this oncogenic pathway. Rather than viewing tumors as chaotic assemblies of rogue cells, this research suggests they may rely on key "conductors" like OSMR to organize their growth and defense strategies. By targeting this central control node instead of scattered downstream effects, researchers may finally have a way to silence glioblastoma's relentless adaptation.